Headquartered in Waltham, MA Fiscal year ends December NASDAQ: RGEN repligen.com
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems used in the manufacture of biological drugs. The company serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Its focus areas span Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins. Repligen manufactures primarily in the U.S. with additional key sites in Estonia, Germany, Ireland, the Netherlands, and Sweden. The company has announced a definitive agreement to acquire BioLife Solutions to accelerate its cell therapy platform, adding a differentiated consumables business with recurring revenue and commercial-stage customer exposure. Repligen carries convertible senior notes due 2028 and maintains over $810 million in cash and marketable securities. Updated
Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not…
Pre-Market Stock Futures: Futures are trading mixed, with the Nasdaq getting hammered after a gangbuster start to the first full trading week of the third quarter. All of the major indices finished…
Wednesday's top analyst upgrades and downgrades included Array Technology, Blink Charging, Carnival, Carrier Global, DocuSign, Fox, Marathon Petroleum, Occidental Petroleum, PagSeguro Digital, Paramount Global, Salesforce, Viking Therapeutics and Williams Companies.
Thursday's top analyst upgrades and downgrades included Amgen, Archer Daniels Midland, Blackstone, Bloom Energy, Carnival, Chevron, Danaher, EQT, KKR, Nike, PACCAR, Plug Power, PulteGroup, QuantumScape and RingCentral.
Tuesday's top analyst upgrades and downgrades included Ally Financial, CarMax, Dominion Energy, Dynatrace, Exelon, GigaCloud Technology, Gilead Sciences, Intuit, KKR, Lowe’s Companies, Morgan Stanley and Tesla.
For health care investors, 2020 looks like a potentially good year after an especially fruitful JPMorgan Healthcare Conference this past week.
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems used in the manufacture of biological drugs. The company serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide.
24/7 Wall St.'s 12-month price target for RGEN is $224.91, rated Buy. The Wall Street consensus target is $196.70. RGEN price prediction →
